In this context, our work highlights a new layer of therapeutic potential for PRMT5 inhibitors, which may have expanded utility in ovarian and breast cancers without mutations in HR genes when combined with PARP inhibitors or chemotherapy, as well as for the treatment of patients with tumors that have developed resistance to PARP inhibitors. This evidence concerns the gene PRMT5 and breast carcinoma.